Stock Analiz

Pulse Biosciences, Inc. (PLSE) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$73M, a net margin of -20794.6%; the best year in this period was 2016 with -$10M.

Over the twelve months to September 30, 2026, revenue was $1M and net income -$84M.

Free cash flow was -$54M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 512% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2020: $020202021: $1M20212022: $70000020222023: $020232024: $020242025: $3500002025$350000
Net income
2016: -$10M162017: -$26M172018: -$38M182019: -$47M192020: -$50M202021: -$64M212022: -$59M222023: -$42M232024: -$54M242025: -$73M25-$73M
Free cash flow
2016: -$8M162017: -$14M172018: -$24M182019: -$35M192020: -$36M202021: -$55M212022: -$47M222023: -$33M232024: -$36M242025: -$54M25-$54M
EPS (diluted)
2016: $-0.86162017: $-1.73172018: $-2.20182019: $-2.26192020: $-2.14202021: $-2.28212022: $-1.72222023: $-0.85232024: $-0.92242025: $-1.0825$-1.08

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1M$350000$0$0$700000$1M$0————
Gross profit$400000-$189000$0$0-$11M-$550000$0————
Operating income-$87M-$77M-$56M-$44M-$58M-$63M-$50M-$48M-$38M-$26M-$10M
Net income-$84M-$73M-$54M-$42M-$59M-$64M-$50M-$47M-$38M-$26M-$10M
EPS (diluted)$-1.21$-1.08$-0.92$-0.85$-1.72$-2.28$-2.14$-2.26$-2.20$-1.73$-0.86
R&D$57M$45M$32M$28M$21M$29M$26M$25M$17M$10M$6M
Revenue growth———−100.0%−50.6%——————

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$63M-$54M-$36M-$33M-$47M-$54M-$35M-$34M-$24M-$11M-$8M
Capital spending-$370000-$315000-$125000-$121000-$401000-$437000-$441000-$608000-$276000-$3M-$64000
Free cash flow-$64M-$54M-$36M-$33M-$47M-$55M-$36M-$35M-$24M-$14M-$8M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$17M$21M$14M$7M$5M$15M$10M$11M$12M$11M$870000

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$81M$118M$44M$61M$29M$20M$7M$51M$3M$16M
Debt—$8M$9M$9M$76M$11M$11M$7M———
Equity—$81M$115M$44M-$2M$36M$23M$31M$66M$46M$25M
Total assets—$95M$132M$59M$78M$54M$41M$42M$71M$50M$26M
Shares (diluted)69M67M58M50M34M28M23M21M17M15M11M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin26.8%-54.0%——-1606.3%-38.8%—————
Operating margin-5821.1%-21982.6%——-8293.9%-4443.9%—————
Net margin-5603.9%-20794.6%——-8357.9%-4489.4%—————
FCF margin-4263.9%-15553.4%——-6773.4%-3845.8%—————
ROIC—-87.2%-45.5%-81.4%-78.8%-134.2%-145.9%-101.1%-44.7%-43.9%-29.7%
ROE—-90.2%-46.7%-95.2%2602.5%-178.4%-217.8%-152.8%-56.6%-55.6%-37.6%

Frequently asked questions

What is Pulse Biosciences’s annual revenue?

$350000 in fiscal 2025 and $1M over the twelve months to September 30, 2026.

How much profit does Pulse Biosciences make?

Net income was -$73M in fiscal 2025 (net margin -20794.6%).

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.